Capital Flow Monitor · Sponsors · CIK 2088152
Triton Therapeutics, Inc.
700 FAIRFIELD AVENUE, SUITE 1, STAMFORD, CT, 06902 · 203-482-3123
Pharmaceuticals · Corporation· inc. DELAWARE true 2025
Fit score
—
Offering
$36.4M
Sold
$36.4M
% sold
100.0%
Investors
4
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2025-10-23 | D ·current | 506(b) | $36.4M | $36.4M | 100.0% | 4 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
-
Paul Fonteyne — Executive Officer / Director, Stamford, CT
3 other raises
- DalCor Pharmaceuticals US, LLC $7.0M of $7.0M · 100.0%
- Allyx Therapeutics, Inc. $26.4M of $30.0M · 88.1%
- Apnimed, Inc. $35.0M of $35.0M · 100.0%
- Annie Mitsak — Director, Boston, MA
-
Timothy Shannon — Director, Stamford, CT
1 other raise
- Quarry Glue Holding Co LLC $19.6M of $33.6M · 58.4%
- Elena Grigoryeva — Director, Princeton, NJ
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.